高级检索
当前位置: 首页 > 详情页

Acute Kidney Injury Induced by Immune Checkpoint Inhibitors in Lung Cancer Patients

| 导出 |

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Chest Radiotherapy, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China. [2]Department of Nephrology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China. [3]Department of Respiratory, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China. [4]Corresponding author.
出处:
ISSN:

摘要:
Immune checkpoint inhibitors (ICIs) are novel immunotherapy drugs that have significantly improved the outcomes of a variety of cancers including lung cancer. However, ICIs could induce immune-related adverse effects (irAEs) characterized by clinical manifestations that resemble autoimmune disorders. The main type of IrAEs in the kidneys is acute kidney injury (AKI). In this review, we describe the types of ICIs targeting lung cancer, especially those approved by the U.S. Food and Drug Administration for clinical trials in lung cancer patients. Next, we summarize current understandings of the mechanisms involved in ICIs-induced AKI. Finally, we highlight further directions to address ICIs-associated AKI for the benefits of lung cancer patients in the clinic.

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2022]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验
JCR分区:
出版当年[2022]版:
Q4 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2024]版:
Q3 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子: 最新[2024版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者:
第一作者机构: [1]Department of Chest Radiotherapy, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42329 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号